Sector News

Sobi names former Shire exec to head North American business

May 1, 2019
Life sciences

Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi.

“Sobi North America is entering a new phase in line with Sobi’s growth strategy, with the workforce growing more than fourfold in just more than a year. The launch of Gamifant [emapalumab] and the integration of Synagis are key to the company’s future and I am delighted to welcome Amy to Sobi for her to take on this challenge,” says Guido Oelkers, chief executive.

Ms Pott was most recently group vice president and US franchise head for Internal Medicine & Oncology at Shire, which has recently been acquired by Japan’s Takeda. She was also group VP for US Commercial Operations at Shire and VP of strategy, planning and analytics at Baxalta, all roles based in Boston. Prior to her roles in the USA, Ms Pott spent 10 years at Baxter, where she held UK and international roles working with both rare diseases and medical devices. During her time in the UK she built up Baxter’s UK & Ireland market access team.

Ms Pott has a strong background in private and public healthcare, having worked as an Associate for APCO Worldwide in London, Sacramento and San Francisco supporting a wide range of public sector companies. Previous to her roles at Baxter and Shire, Pott held positions at the National Institute for Health and Clinical Excellence (NICE) and the NHS Confederation. Amy Pott will be part of the Sobi executive committee.

Source: The Pharma Letter

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.